File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: To compare argon laser peripheral iridoplasty (ALPI) against systemic medications in treatment of acute primary angle-closure: Mid-term results

TitleTo compare argon laser peripheral iridoplasty (ALPI) against systemic medications in treatment of acute primary angle-closure: Mid-term results
Authors
KeywordsAcute primary angle-closure
Argon laser peripheral iridoplasty
Medical treatment
Issue Date2006
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/eye
Citation
Eye, 2006, v. 20 n. 3, p. 309-314 How to Cite?
AbstractPurpose: To compare the clinical outcome of argon laser peripheral iridoplasty (ALPI) against systemic medications in treatment of acute primary angle-closure (APAC). Methods: Consecutive patients with APAC were recruited and randomized to receive one of two treatment options: immediate ALPI or systemic acetazolamide±mannitol. All eyes were followed up for at least 6 months after laser iridotomy. Main outcome measures were intraocular pressure (IOP) and requirement for glaucoma medications. Results: A total of 41 eyes (39 patients) were randomized into the ALPI group, and 38 eyes (32 patients) into the medical treatment group. There were no significant differences between the two groups in sex, age, presenting IOP, and duration of attack. Mean follow-up duration±SD was 15.7 ± 5.8 months. There were no significant differences between the two groups in mean final IOP and requirement for glaucoma medications. Conclusions: There were no statistically significant differences in mean IOP and requirement for glaucoma drugs between APAC eyes treated with ALPI and systemic medications. © 2006 Nature Publishing Group. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/176446
ISSN
2023 Impact Factor: 2.8
2023 SCImago Journal Rankings: 1.373
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, JSMen_US
dc.contributor.authorTham, CCYen_US
dc.contributor.authorChua, JKHen_US
dc.contributor.authorPoon, ASYen_US
dc.contributor.authorChan, JCHen_US
dc.contributor.authorLam, SWen_US
dc.contributor.authorLam, DSCen_US
dc.date.accessioned2012-11-26T09:11:20Z-
dc.date.available2012-11-26T09:11:20Z-
dc.date.issued2006en_US
dc.identifier.citationEye, 2006, v. 20 n. 3, p. 309-314en_US
dc.identifier.issn0950-222Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/176446-
dc.description.abstractPurpose: To compare the clinical outcome of argon laser peripheral iridoplasty (ALPI) against systemic medications in treatment of acute primary angle-closure (APAC). Methods: Consecutive patients with APAC were recruited and randomized to receive one of two treatment options: immediate ALPI or systemic acetazolamide±mannitol. All eyes were followed up for at least 6 months after laser iridotomy. Main outcome measures were intraocular pressure (IOP) and requirement for glaucoma medications. Results: A total of 41 eyes (39 patients) were randomized into the ALPI group, and 38 eyes (32 patients) into the medical treatment group. There were no significant differences between the two groups in sex, age, presenting IOP, and duration of attack. Mean follow-up duration±SD was 15.7 ± 5.8 months. There were no significant differences between the two groups in mean final IOP and requirement for glaucoma medications. Conclusions: There were no statistically significant differences in mean IOP and requirement for glaucoma drugs between APAC eyes treated with ALPI and systemic medications. © 2006 Nature Publishing Group. All rights reserved.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/eyeen_US
dc.relation.ispartofEyeen_US
dc.subjectAcute primary angle-closure-
dc.subjectArgon laser peripheral iridoplasty-
dc.subjectMedical treatment-
dc.subject.meshAcetazolamide - Therapeutic Useen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAntihypertensive Agents - Therapeutic Useen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshGlaucoma, Angle-Closure - Drug Therapy - Surgeryen_US
dc.subject.meshHumansen_US
dc.subject.meshIridectomy - Methodsen_US
dc.subject.meshLaser Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMannitol - Therapeutic Useen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVisual Acuityen_US
dc.titleTo compare argon laser peripheral iridoplasty (ALPI) against systemic medications in treatment of acute primary angle-closure: Mid-term resultsen_US
dc.typeArticleen_US
dc.identifier.emailLai, JSM: laism@hku.hken_US
dc.identifier.authorityLai, JSM=rp00295en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1038/sj.eye.6701867en_US
dc.identifier.pmid16021197-
dc.identifier.scopuseid_2-s2.0-33646243231en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33646243231&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume20en_US
dc.identifier.issue3en_US
dc.identifier.spage309en_US
dc.identifier.epage314en_US
dc.identifier.isiWOS:000235730200007-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLai, JSM=7401939748en_US
dc.identifier.scopusauthoridTham, CCY=7006081241en_US
dc.identifier.scopusauthoridChua, JKH=7005163724en_US
dc.identifier.scopusauthoridPoon, ASY=7103068842en_US
dc.identifier.scopusauthoridChan, JCH=26024354100en_US
dc.identifier.scopusauthoridLam, SW=7402279310en_US
dc.identifier.scopusauthoridLam, DSC=35500200200en_US
dc.identifier.citeulike249486-
dc.identifier.issnl0950-222X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats